{
    "2019-06-11": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Smart Dividend Stocks for the Rest of the Year",
                "features": {
                    "keywords": [
                        "dividend",
                        "stocks",
                        "year"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-06-10",
                "original_text": "Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II",
                "features": {
                    "keywords": [
                        "Roche",
                        "Polivy",
                        "FDA",
                        "Gazyva",
                        "Phase II"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-22",
                "original_text": "Lilly Announces Tradjenta Cardiovascular Outcome Study Data",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Tradjenta",
                        "cardiovascular",
                        "study",
                        "data"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-05-15",
                "original_text": "New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance",
                "features": {
                    "keywords": [
                        "SKYRIZI",
                        "risankizumab",
                        "dermatology",
                        "skin clearance"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-12",
                "original_text": "AbbVie - Unique Mix of Growth, Income Value",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "growth",
                        "income",
                        "value"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2022-11-05",
                "original_text": "Horseman Capital Management’s Return, AUM, and Holdings",
                "features": {
                    "keywords": [
                        "Horseman",
                        "Capital",
                        "Management",
                        "return",
                        "AUM",
                        "holdings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}